Review




Structured Review

Zoom Video Communications Inc zoom platform
Zoom Platform, supplied by Zoom Video Communications Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zoom platform/product/Zoom Video Communications Inc
Average 90 stars, based on 1 article reviews
zoom platform - by Bioz Stars, 2026-05
90/100 stars

Images



Similar Products

90
Zoom Video Communications Inc zoom platform
Zoom Platform, supplied by Zoom Video Communications Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zoom platform/product/Zoom Video Communications Inc
Average 90 stars, based on 1 article reviews
zoom platform - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

99
Sartorius AG incucyte zoom 2000 platform
Incucyte Zoom 2000 Platform, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/incucyte zoom 2000 platform/product/Sartorius AG
Average 99 stars, based on 1 article reviews
incucyte zoom 2000 platform - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

86
Zoom Video Communications Inc accountability act compliant zoom web based platform
Accountability Act Compliant Zoom Web Based Platform, supplied by Zoom Video Communications Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/accountability act compliant zoom web based platform/product/Zoom Video Communications Inc
Average 86 stars, based on 1 article reviews
accountability act compliant zoom web based platform - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

86
Zoom Video Communications Inc videoconference platform zoom
Videoconference Platform Zoom, supplied by Zoom Video Communications Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/videoconference platform zoom/product/Zoom Video Communications Inc
Average 86 stars, based on 1 article reviews
videoconference platform zoom - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

86
Zoom Video Communications Inc hipaa compliant zoom video conferencing platform
Hipaa Compliant Zoom Video Conferencing Platform, supplied by Zoom Video Communications Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hipaa compliant zoom video conferencing platform/product/Zoom Video Communications Inc
Average 86 stars, based on 1 article reviews
hipaa compliant zoom video conferencing platform - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

99
Sartorius AG incucyte zoom platform
a . Cell counts for two SET2 DYRK1A KO clones (14B5 & 11H1) generated by CRISPR/Cas9 and expanded in culture, confirming adverse effect on proliferation by DYRK1A KO over time (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5 by ANOVA). b . Western blot showing the knockout of DYRK1A in the 14B5 & 11H1 SET2 cell clones. Densitometric values normalized to HSC70 (representative of n=3 experiments). c . Cell proliferation assay for SET2 cells transduced with lentiviruses expressing DYRK1A specific shRNA or scramble control (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5, by ANOVA). d . Western blot showing the knockdown of DYRK1A expression in SET2 cells following transduction with lentiviruses expressing target specific shRNA or scramble control. Densitometric values were normalized to actin (representative of n=3 experiments). e . Independent replicate experiment of shRNA knockdown experiments. HEL cells were treated with lentiviruses expressing DYRK1A specific shRNA or scramble control, and placed in the <t>Incucyte</t> for serial cell counts (summary of 3 biological replicates, mean +/- SEM, p<0.001 by ANOVA). f . Knockdown of DYRK1A was validated by qRT-PCR (n=3 replicates, shown are mean +/- SEM, compared by t-test, p-values shown are two-sided). g . Western blots for phosphorylation of LIN52 at S28, FOXO1 at S329, total LIN52 and total FOXO1 protein levels after 4 hours of treatment with increasing doses of the DYRK1A inhibitor EHT1610 in SET2 cells are shown. Densitometric values were normalized to HSC70 and GRB2 protein levels, respectively (representative of n=2 experiments). h . Experimental layout for primary patient experiments. i . Timecourse of viability readouts for primary patient cells on days 1,5,8 post treatment with DYRK1A inhibitors EHT1610 and GNF2133 at 0.1 and 1μM doses. On the y axis is % cell death relative to DMSO control. Each sample (n=5 healthy controls, n=4 non-chr21amp and n=4 chr21amp patients) is shown by a dot, with mean and SD depicted in the boxplot. Significance testing by t-test with Bonferroni correction for multiple testing, shown are the adjusted q values *<0.1 **<0.05, ***<0.001.
Incucyte Zoom Platform, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/incucyte zoom platform/product/Sartorius AG
Average 99 stars, based on 1 article reviews
incucyte zoom platform - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

Image Search Results


a . Cell counts for two SET2 DYRK1A KO clones (14B5 & 11H1) generated by CRISPR/Cas9 and expanded in culture, confirming adverse effect on proliferation by DYRK1A KO over time (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5 by ANOVA). b . Western blot showing the knockout of DYRK1A in the 14B5 & 11H1 SET2 cell clones. Densitometric values normalized to HSC70 (representative of n=3 experiments). c . Cell proliferation assay for SET2 cells transduced with lentiviruses expressing DYRK1A specific shRNA or scramble control (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5, by ANOVA). d . Western blot showing the knockdown of DYRK1A expression in SET2 cells following transduction with lentiviruses expressing target specific shRNA or scramble control. Densitometric values were normalized to actin (representative of n=3 experiments). e . Independent replicate experiment of shRNA knockdown experiments. HEL cells were treated with lentiviruses expressing DYRK1A specific shRNA or scramble control, and placed in the Incucyte for serial cell counts (summary of 3 biological replicates, mean +/- SEM, p<0.001 by ANOVA). f . Knockdown of DYRK1A was validated by qRT-PCR (n=3 replicates, shown are mean +/- SEM, compared by t-test, p-values shown are two-sided). g . Western blots for phosphorylation of LIN52 at S28, FOXO1 at S329, total LIN52 and total FOXO1 protein levels after 4 hours of treatment with increasing doses of the DYRK1A inhibitor EHT1610 in SET2 cells are shown. Densitometric values were normalized to HSC70 and GRB2 protein levels, respectively (representative of n=2 experiments). h . Experimental layout for primary patient experiments. i . Timecourse of viability readouts for primary patient cells on days 1,5,8 post treatment with DYRK1A inhibitors EHT1610 and GNF2133 at 0.1 and 1μM doses. On the y axis is % cell death relative to DMSO control. Each sample (n=5 healthy controls, n=4 non-chr21amp and n=4 chr21amp patients) is shown by a dot, with mean and SD depicted in the boxplot. Significance testing by t-test with Bonferroni correction for multiple testing, shown are the adjusted q values *<0.1 **<0.05, ***<0.001.

Journal: Nature Genetics

Article Title: Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A

doi: 10.1038/s41588-025-02190-6

Figure Lengend Snippet: a . Cell counts for two SET2 DYRK1A KO clones (14B5 & 11H1) generated by CRISPR/Cas9 and expanded in culture, confirming adverse effect on proliferation by DYRK1A KO over time (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5 by ANOVA). b . Western blot showing the knockout of DYRK1A in the 14B5 & 11H1 SET2 cell clones. Densitometric values normalized to HSC70 (representative of n=3 experiments). c . Cell proliferation assay for SET2 cells transduced with lentiviruses expressing DYRK1A specific shRNA or scramble control (Shown are mean +/- SEM, n=3 biological replicates, p<0.05 by day 5, by ANOVA). d . Western blot showing the knockdown of DYRK1A expression in SET2 cells following transduction with lentiviruses expressing target specific shRNA or scramble control. Densitometric values were normalized to actin (representative of n=3 experiments). e . Independent replicate experiment of shRNA knockdown experiments. HEL cells were treated with lentiviruses expressing DYRK1A specific shRNA or scramble control, and placed in the Incucyte for serial cell counts (summary of 3 biological replicates, mean +/- SEM, p<0.001 by ANOVA). f . Knockdown of DYRK1A was validated by qRT-PCR (n=3 replicates, shown are mean +/- SEM, compared by t-test, p-values shown are two-sided). g . Western blots for phosphorylation of LIN52 at S28, FOXO1 at S329, total LIN52 and total FOXO1 protein levels after 4 hours of treatment with increasing doses of the DYRK1A inhibitor EHT1610 in SET2 cells are shown. Densitometric values were normalized to HSC70 and GRB2 protein levels, respectively (representative of n=2 experiments). h . Experimental layout for primary patient experiments. i . Timecourse of viability readouts for primary patient cells on days 1,5,8 post treatment with DYRK1A inhibitors EHT1610 and GNF2133 at 0.1 and 1μM doses. On the y axis is % cell death relative to DMSO control. Each sample (n=5 healthy controls, n=4 non-chr21amp and n=4 chr21amp patients) is shown by a dot, with mean and SD depicted in the boxplot. Significance testing by t-test with Bonferroni correction for multiple testing, shown are the adjusted q values *<0.1 **<0.05, ***<0.001.

Article Snippet: Culture plates were sited into the IncuCyte Live Cell imager, and images were captured using the phase contrast channel and were taken every 4 h in the IncuCyte ZOOM platform (Essen BioSciences).

Techniques: Clone Assay, Generated, CRISPR, Western Blot, Knock-Out, Proliferation Assay, Transduction, Expressing, shRNA, Control, Knockdown, Quantitative RT-PCR, Phospho-proteomics